BASIC INFORMATION

Date & Time: 24 May 2026, 18:08:19 Indian Standard Time

Lecture Handout Prepared from the Teaching Session by: Dr. R. K. Mishra

SUMMARY

This lecture provides a comprehensive overview of the current role and future directions of robotic surgery in gynecologic oncology, with a particular focus on the experiences from the Guildford center. The discussion covers the evolution of robotic platforms, from the primitive ZOOS system to the advanced da Vinci XI and SP systems. A significant portion is dedicated to the application of robotic surgery across different tumor types, including endometrial, cervical, and ovarian cancer. For endometrial cancer, robotic surgery has dramatically increased the rate of minimally invasive procedures, especially in morbidly obese patients, leading to lower conversion rates and improved outcomes. The lecture addresses the controversy surrounding minimally invasive surgery for cervical cancer post-LACC trial, presenting institutional data suggesting favorable outcomes for small tumors (<2 cm) and highlighting the ongoing RACC trial. The expanding role of robotics in ovarian cancer is explored through the MIRAS-FROZEN and LANCE trials, examining its utility in both primary and interval debulking surgery. The discussion also touches upon robotic applications for ovarian transposition, vulvar cancer, and pelvic exenteration. The presentation concludes by emphasizing the ergonomic benefits for surgeons, the importance of structured training for fellows, and the future potential of single-port systems.

KEY KNOWLEDGE POINTS

• Evolution and current landscape of robotic surgical platforms in gynecology.

• Advantages of robotic surgery in the management of endometrial cancer, particularly in patients with morbidly high BMI.

• Surgical techniques and pearls for robotic surgery in morbidly obese patients, including Veress needle entry and trocar placement strategies.

• The controversy and ongoing research (LACC, RACC trials) regarding minimally invasive radical hysterectomy for cervical cancer.

• The role of robotic surgery in ovarian transposition for fertility preservation.

• Emerging evidence and clinical trials (MIRAS, LANCE) on robotic-assisted primary and interval debulking surgery for ovarian cancer.

• The application of robotics in complex procedures such as pelvic exenteration.

• The importance of surgeon ergonomics, well-being, and structured robotic training programs.

INTRODUCTION

The adoption of robotic technology has been a transformative development in the field of minimally invasive gynecologic surgery. Since the first robotic-assisted tubal anastomosis was performed in 1998, robotic platforms have evolved significantly, with the da Vinci system being the most prevalent. This technology offers several advantages over conventional laparoscopy, including 3D-magnified vision, enhanced instrument dexterity, and improved surgeon ergonomics. In gynecologic oncology, where precision and minimal morbidity are paramount, robotic surgery has demonstrated considerable benefits. This lecture will review the evidence, share practical experiences from a high-volume center, and discuss the current and future applications of robotics in the management of endometrial, cervical, and ovarian cancers.

LEARNING OBJECTIVES

• To understand the established and emerging roles of robotic surgery in the management of major gynecologic malignancies.

• To learn practical surgical techniques and pearls for performing robotic surgery, particularly in the challenging cohort of morbidly obese patients.

• To critically evaluate the evidence and controversies surrounding minimally invasive surgery for cervical and ovarian cancers, including the implications of major clinical trials.

• To recognize the importance of structured training, surgeon ergonomics, and multidisciplinary collaboration in a successful robotic surgery program.

CORE CONTENT

1. Evolution of Robotic Surgery in Gynecology

The journey of robotic surgery began in 1998 with the ZOOS robotic system. The field is now dominated by Intuitive Surgical's da Vinci platforms, which have progressed from the initial S and Si models to the current multi-quadrant da Vinci Xi. The latest advancements include the Single Port (SP) system and the da Vinci 5, which incorporates haptic feedback. The Guildford center's program began in 2009, expanding from urology and gynecology to include multiple other surgical specialties. The center now operates four dual-console da Vinci Xi systems, facilitating both complex surgery and training.

2. Endometrial Cancer

The role of minimally invasive surgery for endometrial cancer is well-established, with no evidence of adverse oncological outcomes compared to laparotomy.

2.1. Robotic vs. Conventional Laparoscopy

Compared to conventional laparoscopy, robotic surgery for endometrial cancer is associated with:

• Lower rate of conversion to laparotomy.

• Reduced intraoperative and postoperative complications.

• Decreased blood loss.

• A higher overall utilization of a minimally invasive approach.

2.2. Experience in Morbidly Obese Patients (BMI > 40)

Robotic surgery has been a paradigm shift in managing this challenging patient population.

• Guildford Data (Pre-Robotic vs. 2019):

  • Minimally invasive surgery rate increased from 33% to 93%.

  • Conversion rate dropped from 18% to less than 1%.

• Data on Morbidly Obese Cohort (BMI > 40, n > 230):

  • 100% of patients underwent minimally invasive surgery.

  • Zero conversions to laparotomy were recorded over a 13-year period.

  • This was achieved despite managing increasingly complex cases with higher BMIs.

3. Cervical Cancer

The management of cervical cancer with minimally invasive surgery remains a controversial topic following the Laparoscopic Approach to Cervical Cancer (LACC) trial.

3.1. The LACC Trial and Subsequent Guidelines

The LACC trial demonstrated worse disease-free and overall survival with minimally invasive surgery compared to open surgery. This led to guideline changes from major bodies (NICE, ESGO, BGCS) recommending caution, particularly for tumors >2 cm. Limitations of the LACC trial include the inclusion of low-volume centers, potential lack of surgical standardization, and underrepresentation of robotic surgery. The use of uterine manipulators was identified as a potential contributing factor to the poorer outcomes.

3.2. Institutional Data and the RACC Trial

• Guildford Data (Robotic Radical Hysterectomy, n=90):

  • For tumors <2 cm, 5-year survival was comparable to the open arm of the LACC trial.

  • For tumors <2 cm with no lymphovascular space invasion (LVSI), 5-year survival was 100%.

• The RACC Trial: An ongoing international randomized controlled trial is specifically comparing robotic-assisted radical hysterectomy to laparotomy. It mandates surgical standardization, including the non-use of uterine manipulators, and will provide crucial data on the role of robotics.

3.3. Robotic Ovarian Transposition

This procedure is performed in patients with advanced cervical cancer undergoing primary chemoradiotherapy to preserve ovarian function and enable future oocyte harvesting for surrogacy. The robotic approach allows for ultra-high transposition of the ovaries, placing them superiorly near the liver and spleen, well outside the radiation field. This is achieved by mobilizing the ovary and its pedicle, creating a peritoneal tunnel in the paracolonic gutter, and securing the ovary in its new position.

4. Ovarian Cancer

The application of robotics in ovarian cancer is a developing area, with roles in early-stage disease, completion surgery, and interval debulking surgery (IDS).

4.1. Primary and Completion Surgery (Early Stage)

A meta-analysis of 38 studies (n > 8,000) comparing robotic, laparoscopic, and open approaches found that the robotic approach was associated with:

• Least blood loss.

• Shorter length of hospital stay.

• Reduced complication rates.

• No difference in lymph node yields or 5-year survival compared to open surgery (note: not an RCT).

• The MIRAS-FROZEN Trial: A local pilot RCT is currently evaluating robotic surgery versus laparotomy for complex pelvic masses, with intraoperative frozen section guiding the extent of staging.

4.2. Interval Debulking Surgery (IDS)

Small observational studies have reported high rates of complete cytoreduction (R0) and favorable short-term outcomes. However, robust RCT data is needed.

• The MIRAS Trial (Feasibility Phase): This trial evaluated robotic IDS. Of 20 patients suitable for robotic IDS, the R0 resection rate was 43%, with no conversions to open surgery, significantly less blood loss, and a median length of stay of 1.5 days (vs. 6 days for open). Operating time was comparable between groups.

• The LANCE Trial: A UK-based trial comparing laparoscopic/robotic cytoreduction to laparotomy after neoadjuvant chemotherapy. The pilot phase showed acceptable recruitment and no difference in resection rates. However, only one of 49 cases in the MIS arm was robotic. The full Phase 3 trial is ongoing.

5. Vulvar Cancer and Pelvic Exenteration

• Vulvar Cancer: Robotic inguinal lymph node dissection has been described, but with no clear evidence of reduced complications compared to open techniques, its cost-effectiveness is questionable, especially as sentinel lymph node biopsy becomes the standard.

• Pelvic Exenteration: For recurrent pelvic cancers, robotic-assisted exenteration is associated with reduced morbidity, blood loss, and faster recovery compared to open surgery. A meta-analysis showed no difference in recurrence or overall survival, though long-term oncologic data is still maturing. These complex procedures should be confined to specialized centers with multidisciplinary robotic expertise.

6. The Future: Single-Port (SP) Robotics

The SP platform is being used in select centers. A recent European case series in gynecologic oncology (n=63) concluded it is feasible and safe for a selected patient group, offering superior cosmesis. However, the median BMI in this cohort was 24, and its utility in the morbidly obese population, where multiple arms are often crucial for retraction, remains to be determined.

SURGICAL PEARLS

• Morbidly Obese Patients - Teamwork: Essential to have a dedicated high-risk anesthetic and theater team. Preoperative counseling in a multidisciplinary setting is critical.

• Morbidly Obese Patients - Positioning: The surgeon must be present at the start to ensure correct patient positioning, low enough on the table to avoid clashing with the robot.

• Morbidly Obese Patients - Pneumoperitoneum: For Veress needle entry, go vertically at 90 degrees at the true umbilicus. Do not lift the abdominal wall, as this increases the distance the needle must travel and makes entry more difficult.

• Morbidly Obese Patients - Trocar Placement: Do not commit to trocar sites until after insufflation. Assess abdominal distension and the space between the umbilicus and pelvis to optimize placement, which may be above the umbilicus. Avoid tunneling trocars to maximize instrument range of motion.

• Intraoperative Support: Use of a uterine support device, such as a McCartney tube, can be invaluable for manipulating the uterus and facilitating colpotomy, especially when a uterine manipulator is contraindicated.

• Tactile Feedback: In the absence of haptic feedback, surgeons learn to rely on visual cues (tissue deformation, tearing) to judge tension and force. For cytoreduction, systematic visual inspection of all peritoneal surfaces is key, as one cannot "feel" for subtle disease nodules.

ANESTHETIC AND PHYSIOLOGICAL CONSIDERATIONS

• Operating Pressure: The robotic arms bear the weight of the abdominal wall, allowing for the use of very low insufflation pressures (e.g., 8-10 mmHg), even in morbidly obese patients. This minimizes adverse hemodynamic and respiratory effects, making the anesthetist's job easier and facilitating day-case surgery protocols.

• Stress Response: Minimally invasive surgery, particularly with the small incisions of robotics, is associated with a significantly lower surgical stress response (e.g., lower cortisol levels), less pain, and quicker mobilization compared to open surgery.

COMPLICATIONS AND THEIR MANAGEMENT

While not discussed in detail, the lecture consistently highlights that robotic surgery is associated with a lower rate of intraoperative and postoperative complications, less blood loss, and a significantly lower rate of conversion to laparotomy across various procedures when compared to both open and conventional laparoscopic surgery.

MEDICOLEGAL AND PATIENT SELECTION CONSIDERATIONS

• Informed Consent for Cervical Cancer: Following the LACC trial, it is imperative to have a detailed discussion with patients regarding the risks and benefits of different surgical approaches (open vs. robotic/MIS). For tumors <2 cm, institutional data can be used to counsel patients, allowing for shared decision-making. Participation in a clinical trial like RACC should be offered.

• Uterine Manipulators: In cervical cancer surgery, uterine manipulators are now widely avoided due to concerns they may contribute to tumor spillage and worse outcomes.

• Surgeon Skill and Credentialing: The outcomes of surgical trials are highly dependent on surgeon skill and experience. It is crucial that surgeons undertake structured, accredited training programs (e.g., BIARGS, RCOG, Intuitive-supported) to ensure competency and patient safety before practicing independently.

SUMMARY AND TAKE-HOME MESSAGES

• Robotic surgery has established clear benefits in the management of endometrial cancer, particularly in morbidly obese patients, by enabling a minimally invasive approach with lower conversion rates and morbidity.

• The role of robotics in cervical cancer is being re-evaluated in the RACC trial; current evidence suggests it may be safe for small tumors (<2 cm), but careful patient counseling and shared decision-making are essential.

• For ovarian cancer, robotics is a promising tool for both early-stage disease and interval debulking, with ongoing RCTs (MIRAS, LANCE) set to define its role in improving surgical outcomes and quality of life.

• The ergonomic advantages of robotic surgery are significant, reducing surgeon fatigue and promoting career longevity, which is a critical factor in an era of increasing case complexity and workload.

MULTIPLE CHOICE QUESTIONS (MCQs)

1. According to the Guildford center's data on endometrial cancer surgery, what was the conversion-to-laparotomy rate after adopting robotic surgery?

   a) 18%

   b) 5%

   c) Less than 1%

   d) 10%

2. For morbidly obese patients (BMI > 40) undergoing robotic endometrial cancer surgery at Guildford, what was the reported conversion rate to open surgery over a 13-year period?

   a) 5%

   b) 2%

   c) 1%

   d) 0%

3. What is the recommended technique for Veress needle entry in a morbidly obese patient for robotic surgery?

   a) Palmer's point entry with abdominal lift.

   b) Vertical 90-degree entry at the umbilicus without lifting the abdomen.

   c) Open Hasson technique superior to the umbilicus.

   d) Lateral entry with abdominal lift to thin the fascia.

4. The LACC trial demonstrated worse outcomes for minimally invasive surgery in which type of cancer?

   a) Ovarian cancer

   b) Endometrial cancer

   c) Vulvar cancer

   d) Cervical cancer

5. According to the Guildford data on robotic radical hysterectomy, what was the 5-year survival for patients with tumors <2 cm and no LVSI?

   a) 85%

   b) 92%

   c) 98%

   d) 100%

6. What is the primary aim of the RACC trial?

   a) To compare robotic versus laparoscopic hysterectomy for benign disease.

   b) To compare robotic-assisted radical hysterectomy versus laparotomy for cervical cancer.

   c) To evaluate single-port robotics in endometrial cancer.

   d) To assess neoadjuvant chemotherapy in ovarian cancer.

7. What is a key advantage of the robotic approach for ovarian transposition?

   a) Shorter operating time.

   b) Ability to perform ultra-high transposition of the ovaries.

   c) Lower cost than laparoscopy.

   d) Reduced need for general anesthesia.

8. In the meta-analysis on early-stage ovarian cancer surgery, which approach was associated with the least blood loss?

   a) Open laparotomy

   b) Conventional laparoscopy

   c) Robotic-assisted surgery

   d) Vaginal approach

9. What is the primary objective of the MIRAS-FROZEN pilot trial?

   a) To assess HIPEC in robotic surgery.

   b) To randomize patients with complex pelvic masses to robotic surgery or laparotomy.

   c) To evaluate day-case robotic hysterectomy.

   d) To compare sentinel node biopsy techniques.

10. What did the feasibility phase of the MIRAS trial (robotic IDS) find regarding operating time compared to open surgery?

    a) Significantly longer

    b) Significantly shorter

    c) Comparable

    d) Not measured

11. What was a notable finding in the pilot phase of the LANCE trial regarding the MIS arm?

    a) It exclusively used the single-port robot.

    b) Most cases were performed open due to conversions.

    c) Only one out of 49 MIS cases was robotic.

    d) It showed significantly higher complication rates.

12. A major benefit of using multi-port robotic systems in obese patients is the ability to operate at lower pressures (e.g., 8-10 mmHg). What is the primary reason for this?

    a) The system uses a special gas that requires less pressure.

    b) The robotic arms lift and support the weight of the abdominal wall.

    c) The 3D vision allows for better navigation at low pressure.

    d) Anesthetic agents work more effectively with the robot.

13. The use of a uterine manipulator is now generally avoided in which procedure?

    a) Robotic myomectomy

    b) Robotic hysterectomy for benign disease

    c) Robotic radical hysterectomy for cervical cancer

    d) Robotic sacrocolpopexy

14. What is a potential limitation of the single-port (SP) robotic system mentioned in the lecture?

    a) It cannot be used for hysterectomy.

    b) It has poorer optics than the Xi system.

    c) It may be less suitable for morbidly obese patients due to fewer arms for retraction.

    d) It is not approved for use in gynecologic surgery.

15. What did the speaker identify as a crucial non-patient-related benefit of robotic surgery?

    a) Lower instrument costs.

    b) Shorter setup time.

    c) Improved surgeon well-being and ergonomics.

    d) Easier data collection for research.

16. According to the speaker, what is the recommended timing for deciding on trocar placement in obese patients?

    a) Before the patient is draped.

    b) Based on a preoperative CT scan.

    c) After achieving pneumoperitoneum and observing abdominal distension.

    d) Using a standardized template for all BMIs.

17. The feasibility phase of the MIRAS trial on robotic IDS demonstrated a median length of stay of:

    a) 6 days

    b) 4 days

    c) 1.5 days

    d) 8 hours (day case)

18. What was a significant criticism of the LACC trial's methodology?

    a) It only included patients with very large tumors.

    b) It included centers with low case volumes and potential skill variation.

    c) The follow-up period was too short.

    d) It excluded patients who had neoadjuvant chemotherapy.

19. For which cancer did the lecture suggest there is currently insufficient evidence to justify the cost of robotic surgery for lymph node dissection?

    a) Endometrial cancer

    b) Ovarian cancer

    c) Cervical cancer

    d) Vulvar cancer

20. A meta-analysis comparing MIS versus open pelvic exenteration found what regarding recurrence and overall survival?

    a) MIS had worse survival.

    b) MIS had better survival.

    c) No difference in survival.

    d) Data was inconclusive.

Answer Key:

1.c, 2.d, 3.b, 4.d, 5.d, 6.b, 7.b, 8.c, 9.b, 10.c, 11.c, 12.b, 13.c, 14.c, 15.c, 16.c, 17.c, 18.b, 19.d, 20.c

MOTIVATIONAL MESSAGE FROM DR. R. K. MISHRA

The scalpel, whether held by hand or by robot, is merely an extension of our knowledge and discipline. True surgical excellence is forged not in the ease of the procedure, but in the relentless pursuit of perfection, especially when the path is most challenging.

May your hands remain steady, your judgment sound, and your commitment to learning unending as you serve your patients with skill and compassion.